Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 76

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016', provides in depth analysis on Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted pipeline therapeutics.

The report provides comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)

  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Overview 7
Therapeutics Development 8
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Stage of Development 8
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Therapy Area 9
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Indication 10
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Companies 13
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Universities/Institutes 15
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development 24
Aeterna Zentaris Inc. 24
Alize Pharma SAS 25
AstraZeneca Plc 26
Asubio Pharma Co., Ltd. 27
Motus Therapeutics Inc 28
Pfizer Inc. 29
RaQualia Pharma Inc. 30
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles 31
anamorelin hydrochloride - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
AZ-12861903 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
AZP-531 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DLN-101 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
EXT-400 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
HM-01 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
HM-03 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
HM-04 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
macimorelin acetate - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
PF-05190457 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
relamorelin - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
RQ-00433412 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule to Agonize Ghrelin Receptor for Obesity - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule to Inverse Agonize Ghrelin Receptor for Obesity - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Projects 57
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products 60
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Featured News & Press Releases 62
Jul 18, 2016: Alize Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences 62
Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer 62
Apr 26, 2016: Alize Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome 64
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis 65
Apr 04, 2016: Motus Presents Clinical Proof-of-Concept Results for Relamorelin in the Treatment of Anorexia 65
Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology 66
Jan 19, 2016: Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen 67
Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL 69
Nov 19, 2015: Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen for the evaluation of AGHD 69
Oct 29, 2015: Alize Pharma reports positive safety and efficacy results from a Phase Ib trial of AZP-531 in type 2 diabetes and provides an update on its overall clinical program 70
Sep 09, 2015: Additional data for anamorelin in ROMANA 1 and ROMANA 2 studies 71
Jun 25, 2015: Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD 72
May 26, 2015: Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen in AGHD Meets EMA's Study-Design Expectations 73
May 26, 2015: Alizé Pharma presents clinical results from the AZP-531 program at the American Diabetes Association 75th Scientific Sessions 73
May 20, 2015: Helsinn Group to present data on Anamorelin at 2015 ASCO 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Aeterna Zentaris Inc., H2 2016 24
Pipeline by Alize Pharma SAS, H2 2016 25
Pipeline by AstraZeneca Plc, H2 2016 26
Pipeline by Asubio Pharma Co., Ltd., H2 2016 27
Pipeline by Motus Therapeutics Inc, H2 2016 28
Pipeline by Pfizer Inc., H2 2016 29
Pipeline by RaQualia Pharma Inc., H2 2016 30
Dormant Projects, H2 2016 57
Dormant Projects (Contd..1), H2 2016 58
Dormant Projects (Contd..2), H2 2016 59
Discontinued Products, H2 2016 60
Discontinued Products (Contd..1), H2 2016 61

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Europe Cytokines Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 22-Jun-2017        Price: US 4480 Onwards        Pages: 124
    Cytokines are a large group of small signaling molecules that function extensively in cellular communication. Cytokines are most often associated with various immune modulating molecules that include interleukins, chemokines, and interferons, but can also include other molecules as well. Their use in disease diagnosis and treatment has proven very beneficial over the past number of years as their use as biomarkers has been adopted as a means to understanding disease and therapies. They have expa......
  • Global Phloem Fibre Market Professional Survey Report 2017
    Published: 22-Jun-2017        Price: US 3500 Onwards        Pages: 104
    This report studies Phloem Fibre in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Camira Fabrics - FlexForm Technologies - Bast Fibers LLC - American Hem......
  • North America Ion Indicators Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 21-Jun-2017        Price: US 4480 Onwards        Pages: 118
    This report studies the Ion Indicators market. Ion indicators include mental indicators, PH indicators and so on. Scope of the Report: This report focuses on the Ion Indicators in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and application. Market Segment by Manufacturers, this report covers - Thermo Fisher Scientific - ATT - Abcam ......
  • Global Microbial Growth Media Market 2017-2021
    Published: 21-Jun-2017        Price: US 3500 Onwards        Pages: 71
    Growth media is of great importance for microbiological tests; it helps obtain pure cultures, grow and count microbial cells, and cultivate and select microorganisms. High-quality growth media is important to achieve accurate and reproducible results of microbiological tests. The microbial growth medium encourages the growth of microorganisms. Microbial growth media contains nutrients, growth promoting factors, energy sources, buffer salts, minerals, metals, and gelling agents. It has been us......
  • Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H1 2017
    Published: 20-Jun-2017        Price: US 3500 Onwards        Pages: 54
    Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H1 2017 Summary Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by......
  • Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2017
    Published: 20-Jun-2017        Price: US 3500 Onwards        Pages: 34
    Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2017 Summary Cell Division Protein FtsZ (ftsz) - FtsZ is a protein encoded by the ftsZ gene. It is essential cell division protein that forms a contractile ring structure at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. It recruits other cell division proteins to the septum to produce a new cell wall between the dividing cells. It binds......
  • Global Laser Capture Microdissection Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 20-Jun-2017        Price: US 3480 Onwards        Pages: 120
    Laser Capture Microdissection (LCM) technology is a contagion free process for obtaining sub-populations of tissue cells under direct microscopic apparition. In addition, laser-capture Microdissection technology isolates specific cells by dissecting unwanted cells. Laser Capture Microdissection technology harvests the cells of attention straight to give pure enriched cells. This technology helps in preserving the genuine morphology of the dissected cell or tissue sample. The Laser Capture Microd......
  • Dystrophin (DMD) - Pipeline Review, H1 2017
    Published: 20-Jun-2017        Price: US 3500 Onwards        Pages: 70
    Dystrophin (DMD) - Pipeline Review, H1 2017 Summary According to the recently published report 'Dystrophin (DMD) - Pipeline Review, H1 2017'; Dystrophin (DMD) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. Dystrophin (DMD) - Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts ......
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2017
    Published: 20-Jun-2017        Price: US 3500 Onwards        Pages: 61
    Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2017 Summary Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs